BioSpace News Archive

UroGen Pharma Ltd. today announced that the U.S. Food and Drug Administration (FDA) has cleared UroGen’s Investigational New Drug (IND) application to begin a novel Phase 1 clinical study of the anti-CTLA-4 immunotherapy UGN-301 (zalifrelimab) in patients with recurrent NMIBC.

Aptevo Therapeutics Inc. today announced that a patient with relapsed/refractory acute myeloid leukemia or AML in a monotherapy arm of its on-going Phase 1b trial evaluating adult patients with AML, has received an allogeneic stem cell transplant subsequent to receiving APVO436 and experiencing significant reduction in bone marrow blasts.

Pharvaris today reported financial results for the fourth quarter and year ended December 31, 2021 and provided recent business highlights.

Aldeyra Therapeutics, Inc. today will announce at its 2022 Research & Development Day that three clinical trials of ADX-629, a first-in-class orally administered RASP modulator, generated signs of pharmacodynamic and clinical activity consistent with broad-based reduction in pathologic inflammation.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor.

ReCor Medical Announces Completion of Enrollment in RADIANCE-II Pivotal Trial of the Paradise ™ Ultrasound Renal Denervation System for the Treatment of Uncontrolled Hypertension

Eleusis Holdings Ltd announced today it has received a Notice of Allowance for its proprietary psilocin salt form and accompanying formulations from the US Patent and Trademark Office.

BIONIK Laboratories Reports 15-20% Increase in Therapeutic Gains on InMotion ® Robotic Devices in New Patient Outcomes Data Report.

Emmaus Life Sciences, Inc. announced that the Florida Medicaid Pharmaceutical & Therapeutics Committee has approved adding Endari the company’s prescription-grade L-glutamine oral powder for the treatment of sickle cell disease, to the Florida Medicaid Preferred Drug List, effective April 1, 2022.

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), today announced results from a diabetes market survey commissioned by Oramed from IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.